ATOM BIOSCIENCE & PHARMACEUTICAL
Atom Bioscience is a clinical-stage biotechnology company developing new treatments for inflammatory and metabolic diseases such as chronic gout and non-alcoholic steatohepatitis.
ATOM BIOSCIENCE & PHARMACEUTICAL
Industry:
Biotechnology Health Care
Founded:
2012-01-01
Address:
Suzhou, Jiangsu, China
Country:
China
Website Url:
http://www.atombp.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
160.15 M USD
Technology used in webpage:
Chinese Server Location
Similar Organizations
Allogene Therapeutics
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
Graphene Composites
Graphene Composites is a nano-technology startup that combines graphene with aerogel .
ImmunOs Therapeutics
ImmunOs Therapeutics is a clinical-stage biotechnology company.
KBP Biosciences
A multinational clinical stage biotechnology company.
Lion TCR
Lion TCR is a clinical-stage biotechnology company.
Lyten
Lyten is an advanced materials company that developed Lyten 3D Graphene™
Nuevocor
Nuevocor operates as a preclinical-stage biotech company.
OliX Pharmaceuticals
OliX is a clinical stage biotechnology company.
Panacea Biotec
Panacea Biotec is an Innovation driven Biotechnology company.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
Current Employees Featured
Founder
Investors List
Kaitai Capital
Kaitai Capital investment in Series D - Atom Bioscience & Pharmaceutical
Unifortune
Unifortune investment in Series D - Atom Bioscience & Pharmaceutical
NNFE Fund Management
NNFE Fund Management investment in Series D - Atom Bioscience & Pharmaceutical
HuaJin Securities
HuaJin Securities investment in Series D - Atom Bioscience & Pharmaceutical
Fortune Capital
Fortune Capital investment in Series D - Atom Bioscience & Pharmaceutical
ShenZhen GTJA Investment Group
ShenZhen GTJA Investment Group investment in Series C - Atom Bioscience & Pharmaceutical
Sequoia Capital China
Sequoia Capital China investment in Series C - Atom Bioscience & Pharmaceutical
Kaitai Capital
Kaitai Capital investment in Series C - Atom Bioscience & Pharmaceutical
Kingray Capital
Kingray Capital investment in Series C - Atom Bioscience & Pharmaceutical
Livzon Pharmaceutical Group
Livzon Pharmaceutical Group investment in Series C - Atom Bioscience & Pharmaceutical
Official Site Inspections
http://www.atombp.com Semrush global rank: 12.98 M Semrush visits lastest month: 78
- Host name: 43.143.114.245
- IP address: 43.143.114.245
- Location: Japan
- Latitude: 35.69
- Longitude: 139.69
- Timezone: Asia/Tokyo
More informations about "Atom Bioscience & Pharmaceutical"
Home New - Atom Bioscience
May 21, 2024 Atom Therapeutics (Atom Therapeutics Co., Ltd ) is a clinical stage biotechnology company founded in 2012. Atom is developing best-in-class orally delivered small molecule …See details»
Atom Bioscience - LinkedIn
For more info visit atombp.com #gout # ... Sr. VP of Global Business Development for Atom Bioscience will be at Biotechnology Innovation Organization International Convention to talk about Atom ...See details»
Jiangsu Atom Bioscience & Pharmaceutical Co., Ltd.
JIANGSU, China--(BUSINESS WIRE)-- Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments …See details»
Atom Therapeutics and China Medical System Holdings Enter …
5 days ago Atom Therapeutics and CMS will execute a Contract Sales Organization (CSO) business model. Under the agreement, Atom Therapeutics will receive a substantial sum from …See details»
Atom Bioscience Enrolling Patients in US as Part of a Global Phase …
JIANGSU, China, April 24, 2024--Atom is enrolling patients in the US for a Phase 2b/3 clinical trial for a novel investigational orally administered treatment for chronic gout.See details»
About Atom - Atom Bioscience
Atom Therapeutics is a research-based pharmaceutical company engaged in new drug discovery and development on treatments for inflammatory and metabolic diseases. Among our drugs now in development is ABP-671, a novel …See details»
Atom Bioscience Receives FDA IND Clearance for Clinical Trial of …
Jan 2, 2024 ABP-745 is an oral small molecule drug that also has potential applications for other anti-inflammatory diseases. JIANGSU, China, January 02, 2024--(BUSINESS WIRE)--Atom …See details»
Lingdolinurad - Drug Targets, Indications, Patents - Synapse
5 days ago The company’s lead product, ABP-671, is in clinical development for treatment of chronic gout. Another small molecule ABP-745 has shown significant efficacy and good safety …See details»
Atom Bioscience Announces Positive Phase 2a Results …
Mar 21, 2022 Business Development Contact: Roy J. Wu, MBA Sr. Vice President, Business Development Atom Bioscience and Pharmaceutical Co., Ltd Email: [email protected] Site Navigation HomeSee details»
Atom Bioscience Doses First Patient in Phase 2b/3 Clinical
JIANGSU, China (October 9, 2023) - Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments …See details»
Atom Bioscience Raises $47 Million in Series C Round of Financing …
Jan 5, 2022 Atom Bioscience Raises $47 Million in Series C Round of Financing to Advance Development of Small Molecule Drugs for Inflammatory and Metabolic Diseases Funding will …See details»
ABP-745 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 ABP-745 is an oral small molecule drug that also has potential applications for other anti-inflammatory diseases JIANGSU, China--(BUSINESS WIRE)-- Atom Bioscience …See details»
Atom Bioscience Announces Positive Phase 2a Results For
Mar 21, 2022 JIANGSU, China--(BUSINESS WIRE)-- Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing …See details»
Atom Bioscience Raises $83M in a D-Round Financing to
Oct 16, 2023 The company’s lead product, ABP-671, is in clinical development for treatment of chronic gout. Another small molecule ABP-745 has shown significant efficacy and good safety …See details»
Atom Bioscience Enrolling Patients in US as Part of a Global Phase …
Apr 24, 2024 The company’s lead product, ABP-671, is in clinical development for treatment of chronic gout. Another small molecule ABP-745 has shown significant efficacy and good safety …See details»
Atom Bioscience to Update Clinical Development of New Drug to …
Jun 8, 2022 Atom Bioscience to Update Clinical Development of New Drug to Treat Gout at BIO International Convention, June 13 – 16, 2022, San Diego, CASee details»
Atom Bioscience Doses First Patient in Phase 2b/3 ... - Business Wire
Oct 9, 2023 JIANGSU, China--(BUSINESS WIRE)--Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new …See details»
Atom Bioscience Raises $83M in a D-Round Financing to Support …
Oct 16, 2023 The company’s lead product, ABP-671, is in clinical development for treatment of chronic gout. Another small molecule ABP-745 has shown significant efficacy and good safety …See details»
Atom Bioscience Receives FDA IND Clearance - Business Wire
Jan 2, 2024 Business Development Contact: Roy J. Wu, MBA Sr. Vice President, Business Development Atom Bioscience and Pharmaceutical Co., Ltd Email: [email protected] Site …See details»